Philadelphia Pharmaceuticals Co. (PHIL) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Philadelphia Pharmaceuticals Co.

Dar Al Dawa Development & Investment Co. Ltd.

Hayat Pharmaceutical Industries Co. Ltd.

Why is Philadelphia Pharmaceuticals Co. ?

Positive results in Dec 25

ROCE(HY) Highest at 7.57%
RAW MATERIAL COST(Y) Fallen by -12.93% (YoY)
CASH AND EQV(HY) Highest at JOD 3.43 MM

With ROE of 7.44%, it has a fair valuation with a 0.00 Price to Book Value

Over the past year, while the stock has generated a return of 14.38%, its profits have risen by 19%

Underperformed the market in the last 1 year

The stock has generated a return of 14.38% in the last 1 year, much lower than market (Jordan General Index) returns of 49.15%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Philadelphia Pharmaceuticals Co. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Philadelphia Pharmaceuticals Co. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Philadelphia Pharmaceuticals Co.

14.38%

0.79

19.19%

Jordan General Index

46.42%

4.78

10.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.66%

EBIT Growth (5y)

16.11%

EBIT to Interest (avg)

1.03

Debt to EBITDA (avg)

0.32

Net Debt to Equity (avg)

0.05

Sales to Capital Employed (avg)

0.59

Tax Ratio

21.07%

Dividend Payout Ratio

52.24%

Pledged Shares

Institutional Holding

ROCE (avg)

7.95%

ROE (avg)

4.90%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

-0.50

EV to EBITDA

-0.42

EV to Capital Employed

-0.06

EV to Sales

-0.08

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

7.44%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

ROCE(HY)

Highest at 7.57%

RAW MATERIAL COST(Y)

Fallen by -12.93% (YoY

CASH AND EQV(HY)

Highest at JOD 3.43 MM

DEBT-EQUITY RATIO (HY)

Lowest at -0.5 %

DEBTORS TURNOVER RATIO(HY)

Highest at 1.39 times

PRE-TAX PROFIT(Q)

Highest at JOD 0.43 MM

NET PROFIT(Q)

Highest at JOD 0.34 MM

EPS(Q)

Highest at JOD 0.05

-2What is not working for the Company

DIVIDEND PAYOUT RATIO(Y)

Lowest at 154.19%

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.28 times

Here's what is working for Philadelphia Pharmaceuticals Co.

Pre-Tax Profit

Highest at JOD 0.43 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JOD MM)

Net Profit

Highest at JOD 0.34 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JOD MM)

EPS

Highest at JOD 0.05

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (JOD)

Cash and Eqv

Highest at JOD 3.43 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -0.5 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 1.39 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -12.93% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Philadelphia Pharmaceuticals Co.

Inventory Turnover Ratio

Lowest at 2.28 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Dividend Payout Ratio

Lowest at 154.19%

in the last five years

MOJO Watch

Company is distributing lower proportion of profits generated as dividend

DPR (%)